Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Repros Therapeutics Inc. (“Repros” or the “Company”) (NASDAQ: RPRX).
The investigation focuses on whether the Company and its executives violated federal securities laws by making false and misleading statements and/or failing to disclose material facts regarding its business and operations.
On October 17, 2014, Repros announced that it had received a communication from the Food and Drug Administration “indicating that based on its preliminary review of the Company's briefing document, there was not sufficient clinical information provided for the meeting” regarding its new drug Androxal® “to be a Type B Pre-NDA meeting.”
Following this news, the price of Repros stock declined by $4.20 per share, or nearly 40%, to close on October 17, 2014 at $6.31 per share.
If you invested in Repros stock or options prior to October 17, 2014 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Repros’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.